NARI Stock Forecast 2025-2026
Distance to NARI Price Targets
NARI Price Momentum
10 Quality Stocks Worth Considering Now
Researching Inari Medical (NARI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NARI and similar high-potential opportunities.
Latest NARI Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for NARI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NARI Analyst Ratings
NARI Price Target Range
Latest NARI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NARI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
(NARI) Competitors
The following stocks are similar to Inari Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(NARI) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
(NARI) Business Model
(NARI) Latest News & Analysis
Warren Buffett advises that investors should only buy stocks they are willing to hold for at least 10 years, emphasizing a long-term investment strategy.
Buffett's perspective emphasizes long-term investment strategies, suggesting that volatility shouldn't deter investors from holding solid companies, influencing market sentiment and stock stability.
Stryker (NYSE: SYK) has acquired Inari Medical, Inc. (NASDAQ: NARI), enhancing its position in the venous thromboembolism market with innovative clot removal solutions.
Stryker's acquisition of Inari Medical enhances its portfolio in the lucrative VTE market, potentially driving revenue growth and improving competitive positioning in medical technologies.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Inari Medical (NASDAQ:NARI) investors who bought shares before March 10, 2021. Further details are available on their website.
The investigation into Inari Medical may indicate potential legal issues or misconduct, which could impact stock valuation and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Inari Medical, Inc. (NASDAQ:NARI) investors who bought shares before March 10, 2021. More info at bgandg.com/NARI.
The investigation may indicate potential legal issues for Inari Medical, which could affect stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Inari Medical, Inc. (NASDAQ:NARI) investors who bought shares before March 10, 2021. Visit bgandg.com/NARI for details.
Potential legal claims against Inari Medical could impact the stock's value and investor sentiment, leading to volatility and risk for current shareholders.
Kadant Set to Join S&P SmallCap 600
1 month agoKadant Inc. (NYSE: KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective February 19, 2025, as Stryker Corp. (NYSE: SYK) is acquiring Inari Medical.
Kadant Inc.'s inclusion in the S&P SmallCap 600 may boost its stock price due to increased visibility, while Inari Medical's acquisition can affect investor sentiment and valuation dynamics.
Frequently Asked Questions About NARI Stock
What is 's (NARI) stock forecast for 2025?
Analyst forecasts for (NARI) are not currently available. The stock is trading at $0.00.
Is NARI stock a good investment in 2025?
Analyst ratings for NARI are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NARI stock?
Price predictions from Wall Street analysts for NARI are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for NARI ?
Price targets from Wall Street analysts for NARI are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for NARI ?
Price targets from Wall Street analysts for NARI are not currently available. The stock is trading at $0.00.
What is the overall NARI consensus from analysts for ?
Analyst ratings for NARI are not currently available. The stock is trading at $0.00.
How accurate are NARI stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
